Trials / Unknown
UnknownNCT05172856
A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
A Phase Ib, Open-Label, Multi-Center, Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is open-label, multicenter, Phase Ib study is designed to evaluate the Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI321 | IBI321 at a dose no higher than RP2D, D1 IV Q3W. |
Timeline
- Start date
- 2022-03-01
- Primary completion
- 2023-06-30
- Completion
- 2024-12-31
- First posted
- 2021-12-29
- Last updated
- 2021-12-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05172856. Inclusion in this directory is not an endorsement.